We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-25.41%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$253M
AUM Growth
-$3.7M
Cap. Flow
+$136M
Cap. Flow %
53.73%
Top 10 Hldgs %
59.38%
Holding
46
New
12
Increased
10
Reduced
5
Closed
10

Top Buys

Rank Stock Value
1
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$41.1M
2
ZGNX
Zogenix, Inc.
ZGNX
+$18.9M
3
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$16.4M
4
RLYP
RELYPSA INC COM
RLYP
+$14.5M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$11.8M

Top Sells

Rank Stock Value
1
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$6.77M
2
ASND icon
Ascendis Pharma A/S
ASND
+$5.5M
3
ATRS
Antares Pharma, Inc.
ATRS
+$3.49M
4
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$3.45M
5
XNPT
XENOPORT, INC.
XNPT
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 54%
2 Technology 7.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.63M 1.04%
15,476
+3,374
+28% +$1.22M
ATRS
27
DELISTED
Antares Pharma, Inc.
ATRS
$1.73M 0.69%
1,018,627
-1,781,373
-64% -$3.49M
ALBO
28
DELISTED
Albireo Pharma Inc
ALBO
$1.46M 0.58%
110,566
-23,151
-17% -$583K
NGNE icon
29
Neurogene
NGNE
$656M
$1.41M 0.56%
+5,000
New +$1.15M
OSIR
30
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$1.39M 0.55%
+75,000
New +$1.45M
FLXN
31
CALL
DELISTED
Flexion Therapeutics, Inc.
FLXN
$985K 0.39%
+66,300
New +$1.56M
MTEM
32
CALL
DELISTED
Molecular Templates, Inc.
MTEM
$858K 0.34%
+1,278
New +$909K
TTHI
33
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$800K 0.32%
+447,026
New +$951K
WINT
34
DELISTED
Windtree Therapeutics Inc
WINT
$759K 0.3%
+180,752
New +$1.2M
DSCI
35
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$477K 0.19%
101,235
-178,765
-64% -$1.15M
STRM
36
DELISTED
Streamline Health Solutions
STRM
$347K 0.14%
10,107
– –
ASND icon
37
Ascendis Pharma A/S
ASND
$16B
– –
-311,222
Closed -$5.5M
ENTA icon
38
Enanta Pharmaceuticals
ENTA
$366M
– –
-35,000
Closed -$1.57M
ESPR
39
DELISTED
Esperion Therapeutics
ESPR
– –
-8,400
Closed -$687K
EXEL icon
40
PUT
Exelixis
EXEL
$13.3B
– –
-745,000
Closed -$2.8M
ATHX
41
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-32,308
Closed -$977K
ATHX
42
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
– –
-4,000
Closed -$121K
SGNT
43
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
– –
-141,900
Closed -$3.45M
XNPT
44
DELISTED
XENOPORT, INC.
XNPT
– –
-485,000
Closed -$2.97M
BDSI
45
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-10,300
Closed -$82K
OREX
46
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-44,000
Closed -$2.18M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2015 Portfolio in Review

As of Q3 2015, Great Point Partners held 46 positions worth $253M, down 1.4% from $257M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Great Point Partners deployed $136M of net new capital in Q3 2015, opening 12 new positions and adding to 10 existing holdings. Its largest new stake was Tetraphase Pharmaceuticals, Inc.: 56,000 shares worth $8.36M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 60% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Synergy Pharmaceuticals, Inc Common Stock, an estimated $6.77M trimmed.

  • Great Point Partners's largest Q3 2015 buy was Tetraphase Pharmaceuticals, Inc.: 56,000 shares worth $8.36M.
  • Great Point Partners added most to Zogenix, Inc. in Q3 2015, an estimated $18.9M increase.
  • Great Point Partners's biggest Q3 2015 reduction was Synergy Pharmaceuticals, Inc Common Stock, cutting an estimated $6.77M.
  • Great Point Partners fully exited Ascendis Pharma A/S in Q3 2015, selling an estimated $5.5M.
  • Great Point Partners's ten largest holdings make up 59% of its $253M portfolio in Q3 2015.
  • Great Point Partners opened 12 new positions and closed 10 in Q3 2015.
  • Great Point Partners's portfolio value fell 1.4% quarter-over-quarter to $253M.

Based on Great Point Partners's 13F filing for Q3 2015, filed 16 Nov 2015.